EQUITY RESEARCH - RESULTS FLASH

PRARAM 9 HOSPITAL

THAILAND / HEALTH CARE SERVICES

PR9 TB





TARGET PRICE THB24.00
CLOSE THB17.30
UP/DOWNSIDE +38.7%
TP vs CONSENSUS +6.0%

2Q24 results at first glance

กำไรปกติโต 15% y-y เป็น 139 ลบ. ใกล้เคียงกับที่เราคาด

Highlights

- PR9 รายงานกำไรปกติ 2Q24 อยู่ที่ 139 ลบ. (+15% y-y, -13% q-q) ใกล้เคียงกับที่เรา คาด
- รายได้โต 8% y-y ใน 2Q24 โดยมีรายได้จากผู้ชาวไทยเพิ่ม 5% y-y ในขณะที่รายได้จาก ผู้ป่วยต่างชาติกระโดดเพิ่ม 24% y-y นำโดยรายได้ที่สูงขึ้นจากผู้ป่วยชาวตะวันออกกลาง ลาวและกัมพูชา
- สัดส่วนรายได้จากผู้ป่วยชาวไทยคิดเป็น 85% ของรายได้รวมในขณะที่รายได้จากผู้ป่วย ต่างชาติคิดเป็น 15%
- ค่าใช้จ่ายการขายและบริหารเพิ่ม 10% y-y จากค่าใช้จ่ายการตลาดและการส่งเสริมการขาย
 รวมถึงค่าใช้จ่ายในการซ่อมบำรุงที่สูงขึ้น ต้นทุนขายเพิ่ม 7% y-y ตามรายได้ที่สูงขึ้นซึ่งทำ
 ให้ EBITDA margin ปรับตัวดีขึ้นเป็น 22.4% (เทียบกับ 21.7% ใน 2Q23)
- ทำไรปกติในช่วง 1H24 โต 30% y-y และคิดเป็น 45% ของประมาณการกำไรปกติปี 2024
 ของเราที่ 656 ลบ.

Outlook

 เราคาดว่ากำไรจะโตดีต่อเนื่องใน 3Q24 จาก High season ของธุรกิจ Healthcare นอกจากนี้ PR9 ยังได้เซ็นสัญญากับตัวแทนเพิ่มเมื่อไม่นานมานี้เพื่อดึงผู้ป่วยชาว ตะวันออกกลางให้เข้ามารับการรักษาที่โรงพยาบาลของบริษัทฯ โดยเฉพาะชาวกาตาร์และ สหรัฐอาหรับเอมิเรตส์ ดังนั้นเราจึงคาดว่ารายได้จากผู้ป่วยต่างชาติจะโตดีในช่วง 2H24

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	4,202	4,633	4,915	5,214
Net profit	558	656	720	789
EPS (THB)	0.71	0.83	0.92	1.00
vs Consensus (%)	-	0.7	(0.4)	(2.1)
EBITDA	958	1,107	1,201	1,304
Recurring net profit	558	656	720	789
Core EPS (THB)	0.71	0.83	0.92	1.00
EPS growth (%)	(1.7)	17.5	9.8	9.7
Core P/E (x)	24.4	20.7	18.9	17.2
Dividend yield (%)	1.7	2.4	2.6	2.9
EV/EBITDA (x)	12.2	10.2	9.0	8.0
Price/book (x)	2.7	2.5	2.3	2.2
Net debt/Equity (%)	(37.3)	(42.7)	(46.8)	(50.7)
ROE (%)	11.4	12.4	12.6	12.9



Share price performance	1 Mont	th 3 Month	12 Month			
Absolute (%)	(2.3	3) (8.9)	(4.9)			
Relative to country (%)	(0.6	6) (2.9)	12.9			
Mkt cap (USD m)			381			
3m avg. daily turnover (USD m) 1						
Free float (%)			59			
Major shareholder	Khunying Pot	jaman Dama	pong (37%)			
12m high/low (THB)			19.90/13.10			
Issued shares (m)			786.30			

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFAFundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

Exhibit 1: PR9 – 2Q24 results summary

FY ending Dec	2Q23	3Q23	4Q23	1Q24	2Q24	Cha	inge	2023	2024E	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)				
Sales	1,005	1,066	1,175	1,071	1,084	1	8	4,202	4,633	10
COGS (incl depreciation)	(688)	(714)	(761)	(715)	(733)	3	7	(2,820)	(3,068)	9
Gross profit	316	351	414	356	350	(2)	11	1,382	1,565	13
SG&A	(185)	(198)	(209)	(182)	(204)	12	10	(774)	(820)	6
Operating profit	132	154	205	175	146	(16)	11	608	745	22
Net other income	17	19	28	22	26	18	51	81	75	(8)
Interest expenses	(0)	(0)	(0)	(0)	(0)	(12)	(7)	(1)	0	n/a
Pretax profit	149	173	233	197	173	(12)	16	689	820	19
Income Tax	(28)	(33)	(45)	(38)	(34)	(11)	20	(131)	(164)	25
Core profit	121	140	188	159	139	(13)	15	558	656	18
Extraordinaries, GW & FX										
Reported net profit	121	140	188	159	139	(13)	15	558	656	18
Outstanding shares (m)	786	786	786	786	786	0	0	786	786	0
Pre-ex EPS (THB)	0.15	0.18	0.24	0.20	0.18	(13)	15	0.71	0.83	18
EPS (THB)	0.15	0.18	0.24	0.20	0.18	(13)	15	0.71	0.83	18
COGS excl. depreciation	(616)	(638)	(686)	(640)	(658)	3	7	(2,521)	(2,756)	9
Depreciation	(72)	(76)	(75)	(75)	(76)	1	5	(299)	(312)	4
EBITDA	221	249	308	271	248	(8)	12	988	1,131	15
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	31	33	35	33	32	(1)	1	33	34	1
SG&A/Revenue	18	19	18	17	19	2	0	18	18	(1)
EBITDA margin	21.7	22.9	25.6	24.8	22.4	(2)	1	23	24	1
Net profit margin	12	13	16	15	13	(2)	1	13	14	1
Operating stats	(%)	(%)	(%)	(%)	(%)					
OPD revenue growth y-y	5	4	3	13	10					
OPD volume growth y-y	4	5	4	9	N/A					
OPD revenue per head growth y-y	1	(0)	(1)	4	N/A					
IPD revenue growth y-y	1	(5)	12	11	5					
IPD volume growth y-y	(10)	(11)	13	15	N/A					
IPD revenue per head growth y-y	13	6	(1)	(4)	N/A					
Thai patient revenue growth y-y	4	1	6	10	5					
Inter patient revenue growth y-y	1	(5)	9	25	24					

Sources: PR9; FSSIA estimates

Financial Statements

Praram 9 Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	4,107	4,202	4,633	4,915	5,214
Cost of goods sold	(2,724)	(2,820)	(3,068)	(3,241)	(3,424)
Gross profit	1,384	1,382	1,565	1,674	1,790
Other operating income	43	51	50	50	52
Operating costs	(735)	(774)	(820)	(855)	(891)
Operating EBITDA	991	958	1,107	1,201	1,304
Depreciation	(299)	(299)	(312)	(332)	(353)
Goodwill amortisation	· ,	-	-	` -	-
Operating EBIT	692	659	795	869	951
Net financing costs	8	30	25	31	36
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	0	0	0	0	0
Profit before tax	700	689	820	900	987
Tax	(132)	(131)	(164)	(180)	(197)
Profit after tax	568	558	656	720	789
Minority interests	0	0	0	0	0
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	568	558	656	720	789
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	568	558	656	720	789
Per share (THB)					
Recurring EPS *	0.72	0.71	0.83	0.92	1.00
Reported EPS	0.72	0.71	0.83	0.92	1.00
DPS	0.29	0.30	0.42	0.46	0.50
Diluted shares (used to calculate per share data)	786	786	786	786	786
Growth	700	700	700	700	7.00
Revenue (%)	37.5	2.3	10.3	6.1	6.1
Operating EBITDA (%)	67.9	(3.4)	15.5	8.5	8.6
Operating EBIT (%)	133.3	(4.7)	20.6	9.4	9.4
Recurring EPS (%)	127.8	(1.7)	17.5	9.4	9.7
Reported EPS (%)	127.8	(1.7)	17.5	9.8	9.7
Operating performance	127.0	(1.7)	17.5	3.0	5.1
	33.7	22.0	33.8	34.1	24.2
Gross margin inc. depreciation (%)		32.9			34.3 41.1
Gross margin exc. depreciation (%)	41.0	40.0	40.5	40.8	
Operating EBITDA margin (%)	24.1	22.8	23.9	24.4	25.0
Operating EBIT margin (%)	16.8 13.8	15.7 13.3	17.2	17.7 14.6	18.2 15.1
Net margin (%)	13.8	13.3	14.2	14.6	
Effective tax rate (%)	18.9	19.0	20.0	20.0	20.0
Dividend payout on recurring profit (%)	40.2	42.3	50.0	50.0	50.0 (26.4)
Interest cover (X)	(84.0)	(22.3)	(32.2)	(28.4)	, ,
Inventory days	8.1	7.2	6.7	6.8	6.8
Debtor days	20.2	23.1	22.9	21.5	20.3
Creditor days	82.5	73.9	72.3	73.5	73.5
Operating ROIC (%)	18.1	17.6	20.9	23.0	25.3
ROIC (%)	17.4	16.1	18.9	20.8	22.9
ROE (%)	12.6	11.4	12.4	12.6	12.9
ROA (%)	10.5	9.3	10.3	10.5	10.8
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
OPD patient revenue	2,383	2,491	2,746	2,913	3,091
IPD patient revenue	1,725	1,711	1,887	2,002	2,124
Sources: Praram 9 Hospital: ESSIA estimates					

Sources: Praram 9 Hospital; FSSIA estimates

Financial Statements

Praram 9 Hospital

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	568	558	656	720	789
Depreciation	299	299	312	332	353
Associates & minorities	-	-	-	-	-
Other non-cash items	10	10	0	0	0
Change in working capital	(5)	(23)	54	35	37
Cash flow from operations	871	844	1,021	1,087	1,179
Capex - maintenance	(140)	(326)	(330)	(350)	(371)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	(150)	(100)	0	0	0
Other investments (net)	-	-	-	-	-
Cash flow from investing	(290)	(426)	(330)	(350)	(371)
Dividends paid	(110)	(234)	(236)	(328)	(360)
Equity finance	0	0	0	0	0
Debt finance	2	1	0	0	0
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(108)	(233)	(236)	(328)	(360)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	473	184	456	409	448
Free cash flow to firm (FCFF)	581.44	418.17	691.50	736.80	808.12
Free cash flow to equity (FCFE)	582.47	418.73	691.50	736.80	808.12
Per share (THB)					
FCFF per share	0.74	0.53	0.88	0.94	1.03
FCFE per share	0.74	0.53	0.88	0.94	1.03
Recurring cash flow per share	1.11	1.10	1.23	1.34	1.45
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Tangible fixed assets (gross)	5,638	5,898	6,228	6,578	6,949
Less: Accumulated depreciation	(2,322)	(2,556)	(2,867)	(3,199)	(3,552)
Tangible fixed assets (net)	3,315	3,343	3,361	3,379	3,397
Intangible fixed assets (net)	0	0	0	0	0
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	154	254	254	254	254
Cash & equivalents	1,717	1,901	2,357	2,766	3,214
A/C receivable	243	290	290	290	290
Inventories	51	48	53	56	59
Other current assets	12	12	13	14	15
Current assets	2,023	2,251	2,713	3,125	3,578
Other assets	65	62	62	62	62
Total assets	5,558	5,910	6,389	6,820	7,290
Common equity	4,735	5,080	5,499	5,892	6,321
Minorities etc.	0	0	0	0	0
Total shareholders' equity	4,735	5,080	5,499	5,892	6,321
Long term debt	8	9	9	9	9
Other long-term liabilities	209	195	195	195	195
Long-term liabilities	217	204	204	204	204
A/C payable	499	522	570	602	635
Short term debt	0	0	0	0	0
Other current liabilities	106	105	115	122	130
Current liabilities	606	626	686	724	765
Total liabilities and shareholders' equity	5,558	5,910	6,389	6,820	7,290
Net working capital	(299)	(276)	(330)	(365)	(402)
Invested capital	3,235	3,382	3,347	3,330	3,311
* Includes convertibles and preferred stock which is bein	ng treated as debt				
Per share (THB)					
Book value per share	6.02	6.46	6.99	7.49	8.04
Tangible book value per share	6.02	6.46	6.99	7.49	8.04
Financial strength					
Net debt/equity (%)	(36.1)	(37.3)	(42.7)	(46.8)	(50.7)
Net debt/total assets (%)	(30.8)	(32.0)	(36.8)	(40.4)	(44.0)
Current ratio (x)	3.3	3.6	4.0	4.3	4.7
CF interest cover (x)	(69.7)	(13.2)	(27.0)	(23.0)	(21.5)
Valuation	2022	2023	2024E	2025E	2026E
Recurring P/E (x) *	24.0	24.4	20.7	18.9	17.2
Recurring P/E @ target price (x) *	33.2	33.8	28.8	26.2	23.9
Reported P/E (x)	24.0	24.4	20.7	18.9	17.2
Dividend yield (%)	1.7	1.7	2.4	2.6	2.9
Price/book (x)	2.9	2.7	2.5	2.3	2.2
Price/tangible book (x)	2.9	2.7	2.5	2.3	2.2
· · · · · · · · · · · · · · · · · · ·	12.0	12.2	10.2	9.0	8.0
EV/EBITDA (x) **	12.0				0
EV/EBITDA (x) ** EV/EBITDA @ target price (x) **	17.3	17.7	14.9	13.4	12.0
EV/EBITDA (x) ** EV/EBITDA @ target price (x) ** EV/invested capital (x)				13.4 3.3	12.0 3.1

Sources: Praram 9 Hospital; FSSIA estimates

Praram 9 Hospital PCL (PR9 TB)



Exhibit 2: FSSIA ESG score implication

54.08 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
***	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 3: ESG – peer comparison

	FSSIA			Dome	stic ratings	;		Global ratings						Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
ВН	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Υ	Υ	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	2.33	2.43
BESG environmental pillar score	_	2.56	2.18
BESG social pillar score	_	1.36	1.52
BESG governance pillar score	_	4.13	4.46
ESG disclosure score	_	37.90	37.90
Environmental disclosure score	_	11.78	11.78
Social disclosure score	_	20.68	20.68
Governance disclosure score	_	81.10	81.10
Environmental			
Emissions reduction initiatives	No	Yes	Yes
Climate change policy	No	Yes	Yes
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	_	0	0
GHG scope 2 location-based	_	4	6
GHG Scope 3	_	0	5
Carbon per unit of production	_	_	_
Biodiversity policy	No	No	No
Energy efficiency policy	No	Yes	Yes
Total energy consumption	_	7	13
Renewable energy use	_	_	_
Electricity used	_	_	_
Fuel used - natural gas	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 5: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 202
Fuel used - crude oil/diesel	No	No	N
Waste reduction policy	No	Yes	Ye
Hazardous waste	_	_	-
Total waste	_	_	-
Waste recycled	_	_	-
Waste sent to landfills	_	_	-
Environmental supply chain management	No	No	N
Water policy	No	Yes	Ye
Water consumption	_	60	15
Social			
Human rights policy	Yes	Yes	Υe
Policy against child labor	No	Yes	Ye
Quality assurance and recall policy	No	Yes	Ye
Consumer data protection policy	No	Yes	Ye
Equal opportunity policy	Yes	Yes	Ye
Gender pay gap breakout	No	No	١
Pct women in workforce	_	_	
Pct disabled in workforce	_	_	
Business ethics policy	No	Yes	Ye
Anti-bribery ethics policy	Yes	Yes	Y
Health and safety policy	No	Yes	Y
Lost time incident rate - employees	_	_	
Total recordable incident rate - employees	_	1	
Training policy	Yes	Yes	Y
Fair remuneration policy	No	No	1
Number of employees – CSR	2,083	1,987	2,0
Employee turnover pct	=	11	_,0
Total hours spent by firm - employee training	14,566	13,462	66,85
Social supply chain management	No	No	N
Governance			•
Board size	10	10	
No. of independent directors (ID)	4	7	
No. of women on board	2	2	
No. of non-executive directors on board	7	7	
Company conducts board evaluations	Yes	Yes	Y
No. of board meetings for the year	7	7	
Board meeting attendance pct	97	100	
Board duration (years)	3	3	
Director share ownership guidelines	No	No	ı
Age of the youngest director	56	56	
Age of the oldest director	72	73	
lo. of executives / company managers	7	5	
No. of female executives	2	0	
Executive share ownership guidelines	No	No	1
Size of audit committee	3	3	
No. of ID on audit committee	3	3	
Audit committee meetings	4	4	
Audit meeting attendance %	100	100	1
Size of compensation committee	3	3	
No. of ID on compensation committee	3	2	
No. of compensation committee meetings	2	2	
Compensation meeting attendance %	83	100	1
Size of nomination committee	3	3	
No. of nomination committee meetings	2	2	
Nomination meeting attendance %	83	100	10
Sustainability governance			
Verification type	No	No	١

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	у			Rating				
The Dow Jones Sustainability Indices (<u>DJSI</u>) By S&P Global	process bas from the ann	ed on the com	transparent, rules-based panies' Total Sustainabil al Corporate Sustainabili anies within each industr	ity Scores resulting ty Assessment (CSA).	Sustainability A ESG Score of I	ssessment (Cess than 45% are disqual	he annual S&P (SA) for DJSI. Co of the S&P Glob ified. The constit iverse.	ompanies with al ESG Score	an S&P Globa of the highest
Sustainability Investment List (THSI) by The Stock Exchange of Thailand (SET)	managing b Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with transt pass the lar trading of the shareholders some key disquependent direct related to CG,	lity in Environmental and ansparency in Governand preemptive criteria, with he board members and extended , and combined holding in ualifying criteria include: tors and free float violation social & environmental in arnings in red for > 3 year	ce, updated annually. two crucial conditions: kecutives; and 2) free nust be >15% of paid- 1) CG score of below on; 3) executives' mpacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) market capitalization > THB5b (-USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI lndex is a market capitalisation-weighted index, cap 5% quarterly weight a maximum, and no cap for number of stocks.				
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by Thailand (SI	the Thai IOD,	h in sustainable developr with support from the Sto is are from the perspectiv s.	ck Exchange of	Good (80-89), and not rated for equitable treatr	3 for Good (70 or scores belo nent of shareh (5%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 ssure & transpare	60-69), 1 for P s include: 1) th 5% combined	ass (60-69), le rights; 2) an); 3) the role of
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), circulation of s exercised. The and verifiability	re incorporated and sufficiently are CG componer AGM proced and after the resufficient informate second assessity; and 3) openned	which shareholders' rights into business operations y disclosed. All form impoents to be evaluated ann ures before the meeting (10%). (The first a tion for voting; and 2) facilitations in the ease of attending mess for Q&A. The third involves, resolutions and voting res	s and information is ortant elements of two ually. The assessment (45%), at the meeting ssesses 1) advance ing how voting rights can be eetings; 2) transparency s the meeting minutes that			o four categories: · (80-89), and not		
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishme policies. The (Companies of Declaration of Certification, in managers and	ent of key contr e Certification in deciding to become function Intent to kick off including risk assignment	Checklist include corruptions, and the monitoring as good for three years. Be a CAC certified member st an 18-month deadline to subsessment, in place of policy are ablishment of whistleblowing at takeholders.)	nd developing of tart by submitting a mit the CAC Checklist for nd control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.				
Morningstar Sustainalytics	based on ar risk is unma	n assessment of naged. Sources	sk rating provides an ove of how much of a compar s to be reviewed include corp her media, NGO reports/webs	ny's exposure to ESG orate publications and	more risk is un	managed, the	score is the sum higher ESG risk	is scored.	
		ompany feedbac Juality & peer rev	k, ESG controversies, issuer : iews.	feedback on draft ESG	NEGL 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+
ESG Book	positioned to the principle helps explai over-weighti	o outperform o of financial mandial manuscription of the output of the o	sustainable companies the ver the long term. The materiality including informal diusted performance. Mat the higher materiality and orly basis.	ethodology considers ation that significantly teriality is applied by	The total ESG scores using m	score is calcul ateriality-base	lated as a weight ad weights. The s adicating better p	ed sum of the	features
MSCI			measure a company's mand laggards according to						nethodology to
	AAA	8.571-10.00	0						
	AA	7.143-8.570	Leader:	leading its industry in ma	anaging the most s	yılılıcant ESG fi	sks and opportunitie	55	
	Α	5.714-7.142	2						
	BBB	4.286-5.713	Average:	a mixed or unexceptional industry peers	al track record of ma	anaging the mos	st significant ESG ris	sks and opportu	nities relative to
	ВВ	2.857-4.285	5	, ,					
	В	1.429-2.856	Laggard:	lagging its industry base	d on its high expos	ure and failure to	o manage significar	nt ESG risks	
	CCC	0.000-1.428					go orgrinioar		
Moody's ESG colutions	believes tha	t a company ir	gree to which companies integrating ESG factors into a shareholders over the i	to its business model and					
Refinitiv ESG rating	based on pu	ublicly available	and objectively measure and auditable data. The ta publicly. (Score ratings a	score ranges from 0 to	100 on relative E	SG performar	nce and insufficie	nt degree of t	
S&P Global			re is a relative score mea in the same industry clas				of ESG risks, op	portunities, an	d impacts
Bloomberg	ESG Score	ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.							
			or r mar occioc, micro				•		

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
20-Aug-2021 10-Jan-2022 22-Apr-2022	BUY BUY BUY	14.00 15.00 16.50	12-Jul-2022 11-Oct-2022 17-Jan-2023	BUY BUY BUY	18.00 21.00 22.00	10-Apr-2024	BUY	24.00

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Praram 9 Hospital	PR9 TB	THB 17.30	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 07-Aug-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.